Jefferies raised the firm's price target on Cibus to $3 from $1.90 and keeps a Hold rating on the shares. With the capital raise in January and cost cutting measures, Cibus aims tot have ample cash for operating expenses and capex through at least 3Q26, the analyst tells investors in a research note. With EU genetic engineering regulations likely finalized in Q2, the firm expects a pickup in customer engagement in trait insertion, single-cell cloning, field trial efficiency solutions, and biofragrance production.
